tiprankstipranks
Trending News
More News >
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
US Market

4D Molecular Therapeutics (FDMT) Ratios

Compare
354 Followers

4D Molecular Therapeutics Ratios

FDMT's free cash flow for Q4 2024 was $3.22K. For the 2024 fiscal year, FDMT's free cash flow was decreased by $ and operating cash flow was $-56.12K. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
14.92 15.65 14.02 19.31 16.88
Quick Ratio
14.92 15.65 14.39 19.83 16.88
Cash Ratio
5.12 13.14 13.90 19.31 16.53
Solvency Ratio
-3.23 -2.97 -3.19 -0.12 -1.72
Operating Cash Flow Ratio
-4.62 -4.00 -5.51 -4.23 -3.04
Short-Term Operating Cash Flow Coverage
-23.88 0.00 -32.65 -56.16 0.00
Net Current Asset Value
$ 385.15M$ 264.53M$ 190.00M$ -245.05M$ 250.71M
Leverage Ratios
Debt-to-Assets Ratio
0.04 0.04 0.06 0.05 0.00
Debt-to-Equity Ratio
0.05 0.05 -0.05 -0.08 0.00
Debt-to-Capital Ratio
0.05 0.05 -0.05 -0.09 0.00
Long-Term Debt-to-Capital Ratio
0.04 0.00 0.00 0.00 0.00
Financial Leverage Ratio
1.10 1.10 -0.83 -1.71 1.12
Debt Service Coverage Ratio
-33.32 0.00 -37.56 -53.04 0.00
Interest Coverage Ratio
0.00 0.00 0.00 0.00 0.00
Debt to Market Cap
0.08 0.00 <0.01 <0.01 0.00
Interest Debt Per Share
0.46 0.37 0.50 0.59 0.00
Net Debt to EBITDA
0.66 2.19 1.91 4.38 5.01
Profitability Margins
Gross Profit Margin
100.00%-368.54%-24.00%83.26%-289.64%
EBIT Margin
-507678.38%-544.65%-3516.52%-395.46%-416.28%
EBITDA Margin
-507678.38%-516.90%-3392.52%-378.72%-405.68%
Operating Profit Margin
-507678.38%-544.65%-3516.52%-395.46%-416.28%
Pretax Profit Margin
-434778.38%-486.59%-3435.41%-395.37%-416.49%
Net Profit Margin
-434778.38%-486.59%-3230.30%-378.63%-415.38%
Continuous Operations Profit Margin
-434778.38%-486.59%-3435.41%-395.37%-416.49%
Net Income Per EBT
100.00%100.00%94.03%95.77%99.73%
EBT Per EBIT
85.64%89.34%97.69%99.98%100.05%
Return on Assets (ROA)
-28.71%-29.67%-38.60%-19.32%-19.61%
Return on Equity (ROE)
-31.51%-32.76%32.14%32.99%-22.05%
Return on Capital Employed (ROCE)
-35.36%-35.17%-44.71%-21.16%-20.86%
Return on Invested Capital (ROIC)
-34.99%-34.83%-41.15%-20.11%-20.81%
Return on Tangible Assets
-28.71%-29.67%-38.60%-19.32%-19.61%
Earnings Yield
-53.54%-12.72%-14.07%-11.23%-5.11%
Efficiency Ratios
Receivables Turnover
0.00 0.00 0.00 383.79 9.16
Payables Turnover
0.00 27.62 1.17 0.63 29.68
Inventory Turnover
0.00 0.00 -0.67 -0.36 0.00
Fixed Asset Turnover
<0.01 0.65 0.09 0.62 2.68
Asset Turnover
<0.01 0.06 0.01 0.05 0.05
Working Capital Turnover Ratio
<0.01 0.09 0.01 0.06 0.09
Cash Conversion Cycle
0.00 -13.21 -857.00 -1.60K 27.55
Days of Sales Outstanding
0.00 0.00 0.00 0.95 39.85
Days of Inventory Outstanding
0.00 0.00 -544.49 -1.03K 0.00
Days of Payables Outstanding
0.00 13.21 312.51 575.78 12.30
Operating Cycle
0.00 0.00 -544.49 -1.03K 39.85
Cash Flow Ratios
Operating Cash Flow Per Share
-2.49 -1.94 -2.68 -2.49 -1.91
Free Cash Flow Per Share
-2.49 -2.01 -3.04 -2.82 -1.95
CapEx Per Share
0.00 0.07 0.36 0.33 0.04
Free Cash Flow to Operating Cash Flow
1.00 1.04 1.13 1.13 1.02
Dividend Paid and CapEx Coverage Ratio
0.00 -27.35 -7.51 -7.59 -50.91
Capital Expenditure Coverage Ratio
0.00 -27.35 -7.51 -7.59 -50.91
Operating Cash Flow Coverage Ratio
-5.47 -5.17 -5.38 -4.20 0.00
Operating Cash Flow to Sales Ratio
-3.64K -3.66 -27.70 -3.83 -3.74
Free Cash Flow Yield
-44.79%-9.91%-13.67%-12.86%-4.69%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-1.87 -7.86 -7.11 -8.91 -19.56
Price-to-Sales (P/S) Ratio
8.12K 38.26 229.63 33.73 81.25
Price-to-Book (P/B) Ratio
0.59 2.58 -2.28 -2.94 4.31
Price-to-Free Cash Flow (P/FCF) Ratio
-2.23 -10.09 -7.32 -7.78 -21.31
Price-to-Operating Cash Flow Ratio
-2.23 -10.46 -8.29 -8.80 -21.72
Price-to-Earnings Growth (PEG) Ratio
-0.12 0.45 -0.26 -0.56 -3.26
Price-to-Fair Value
0.59 2.58 -2.28 -2.94 4.31
Enterprise Value Multiple
-0.94 -5.21 -4.86 -4.53 -15.02
EV to EBITDA
-0.94 -5.21 -4.86 -4.53 -15.02
EV to Sales
4.75K 26.94 164.91 17.15 60.92
EV to Free Cash Flow
-1.31 -7.11 -5.25 -3.95 -15.97
EV to Operating Cash Flow
-1.31 -7.37 -5.95 -4.48 -16.29
Tangible Book Value Per Share
9.47 7.87 7.15 -7.46 9.61
Shareholders’ Equity Per Share
9.47 7.87 -9.72 -7.46 9.61
Tax and Other Ratios
Effective Tax Rate
0.00 0.00 0.06 0.04 <0.01
Revenue Per Share
<0.01 0.53 0.10 0.65 0.51
Net Income Per Share
-2.98 -2.58 -3.12 -2.46 -2.12
Tax Burden
1.00 1.00 0.94 0.96 1.00
Interest Burden
0.86 0.89 0.98 1.00 1.00
Research & Development to Revenue
3.82K 4.69 25.65 3.40 3.90
SG&A to Revenue
1.26K 1.76 10.52 1.55 1.27
Stock-Based Compensation to Revenue
705.84 0.95 5.47 0.76 0.37
Income Quality
0.84 0.75 0.81 0.97 0.90
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis